SOUTH SAN FRANCISCO, Calif., June 11 /PRNewswire/ -- iZumi Bio, Inc., a biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells, today announced the appointment of Corey S. Goodman, Ph.D., to the company's board of directors and scientific advisory board. Dr. Goodman most recently served as president of Pfizer's Biotherapeutics and Bioinnovation Center.
"Dr. Goodman's drug discovery and development expertise will be instrumental as we apply our iPS technology to the development of new therapeutics for unmet medical needs. We will look to Dr. Goodman's extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular atrophy and Parkinson's disease," said John P. Walker, chief executive officer of iZumi. "Over the next few months, we intend to build a world-renowned scientific advisory board, in order to provide guidance and scientific direction for both our proprietary neurodegenerative programs and for additional disease areas, such as metabolic disease, that we plan to pursue through partnerships."
"iZumi's approach opens a new door for stem cell research and its application to therapeutic discovery, and I am excited to work with the company to identify new treatment options for patients suffering from difficult-to-treat conditions including neurodegenerative diseases," said Dr. Goodman.
Prior to joining Pfizer, Dr. Goodman served as the president and chief executive officer of Renovis from 2001 until 2007, when the company merged with Evotec. He has advised numerous biotechnology companies, and co-founded two companies, including Exelixis and Renovis.
Dr. Goodman was a professor at
|SOURCE iZumi Bio, Inc.|
Copyright©2009 PR Newswire.
All rights reserved